<DOC>
	<DOCNO>NCT01374516</DOCNO>
	<brief_summary>The aim study assess efficacy sanofi pasteur 's CYD dengue vaccine prevent symptomatic virologically-confirmed dengue case dengue-endemic area Latin America . Primary Objective : To assess efficacy CYD dengue vaccine 3 vaccination 0 , 6 , 12 month prevent symptomatic virologically-confirmed dengue case , regardless severity , due four serotypes child adolescent age 9 16 year time inclusion . Secondary Objectives : To describe occurrence serious adverse event ( SAEs ) , include SAEs special interest subject throughout trial period . To describe efficacy CYD dengue vaccine dose : - Preventing symptomatic virologically-confirmed dengue case due four serotypes - Preventing symptomatic dengue case , either virologically-confirmed probable base serological criterion , due four serotypes</brief_summary>
	<brief_title>Study Novel Tetravalent Dengue Vaccine Healthy Children Adolescents Aged 9 16 Years Latin America</brief_title>
	<detailed_description>Participants randomize either receive total 3 injection CYD dengue vaccine placebo 0 , 6 , 12 month , respectively . A subset participant country also evaluate reactogenicity immunogenicity enable generation country-specific data reactogenicity , immunogenicity , baseline dengue yellow few antibody level .</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Hemorrhagic Fevers , Viral</mesh_term>
	<mesh_term>Severe Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 9 16 year day inclusion resident site zone Subject good health , base medical history physical examination Assent form inform consent form sign date subject ( base local regulation ) , informed consent form sign dated parent ( ) another legally acceptable representative ( independent witness require local regulation ) Subject able attend schedule visit comply trial procedure . Subject pregnant , lactating , childbearing potential ( consider nonchildbearing potential , female must premenarche least 1 year , surgically sterile , use effective method contraception abstinence least 4 week prior first vaccination least 4 week last vaccination ) . Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial vaccination Planned participation another clinical trial present trial period Selfreported suspect congenital acquired immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) Selfreported seropositivity Human Immunodeficiency Virus ( HIV ) infection Selfreported systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine use trial vaccine contain substance Chronic illness , opinion Investigator , stage might interfere trial conduct completion Receipt blood bloodderived product past 3 month , might interfere assessment immune response Planned receipt vaccine 4 week follow trial vaccination Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol abuse drug addiction may interfere subject 's ability comply trial procedure Identified site employee Investigator study center , direct involvement propose study study direction Investigator study center , well family member ( i.e. , immediate , husband , wife child , adopt natural ) site employee Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Dengue Virus</keyword>
	<keyword>Dengue fever</keyword>
	<keyword>Dengue Hemorrhagic Fever</keyword>
	<keyword>CYD dengue vaccine</keyword>
	<keyword>Flavivirus</keyword>
	<keyword>Dengue Disease</keyword>
</DOC>